Atezolizumab (atezo) plus nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph Ib trial

被引：2
|
作者：
Pohlmann, Paula R. [1 ]
Diamond, Jennifer R. [2 ]
Hamilton, Erika [3 ,4 ]
Tolaney, Sara M. [5 ]
Zhang, Wei [6 ]
Iizuka, Koho [6 ]
Foster, Paul [6 ]
Molinero, Luciana [6 ]
Funke, Roel [6 ]
Adams, Sylvia [7 ]
机构：
[1] MedStar Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, Washington, DC USA
[2] Univ Colorado, Ctr Canc, Aurora, CO USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Tennessee Oncol, Nashville, TN USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] NYU, Langone Med Ctr, New York, NY USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-CT028
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT028
引用
收藏
页数：2
相关论文
共 50 条
  • [21] IMpassion130: a Phase III randomized trial of atezolizumab with nab-paclitaxel for first-line treatment of patients with metastatic triple-negative breast cancer (mTNBC).
    Emens, Leisha A.
    Adams, Sylvia
    Loi, Sherene
    Schneeweiss, Andreas
    Rugo, Hope S.
    Winer, Eric P.
    Barrios, Carlos H.
    Dieras, Veronique
    de la Haba-Rodriguez, Juan
    Gianni, Luca
    Chui, Stephen Y.
    Schmid, Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [22] IMpassion130: Atezolizumab and nab-Paclitaxel Combination in Patients with triple-negative Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (10) : 1076 - +
  • [23] Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).
    Yam, Clinton
    Mittendorf, Elizabeth A.
    Sun, Ryan
    Huo, Lei
    Damodaran, Senthil
    Rauch, Gaiane M.
    Candelaria, Rosalind P.
    Adrada, Beatriz E.
    Seth, Sahil
    Symmans, William Fraser
    Murthy, Rashmi Krishna
    White, Jason B.
    Ravenberg, Elizabeth
    Clayborn, Alyson
    Prabhakaran, Sabitha
    Valero, Vicente
    Thompson, Alastair Mark
    Tripathy, Debu
    Moulder, Stacy L.
    Litton, Jennifer Keating
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [24] Pilot study of carboplatin, nab-paclitaxel and pembrolizumab for metastatic triple-negative breast cancer
    Baar, Joseph
    Abraham, Jame
    Budd, G. Thomas
    Silverman, Paula
    Montero, Alberto
    Moore, Halle
    Fu, Pingfu
    Varadan, Vinay
    Ladaika, Kara
    Hricik, Lauren
    CANCER RESEARCH, 2021, 81 (04)
  • [25] IMpassion130: Results from a global, randomised, double-blind, phase III study of atezolizumab (atezo) plus nab-paclitaxel (nab-P) vs placebo plus nab-P in treatment-naive, locally advanced or metastatic triple-negative breast cancer (mTNBC)
    Schmid, P.
    Adams, S.
    Rugo, H. S.
    Schneeweiss, A.
    Barrios, C. H.
    Iwata, H.
    Dieras, V.
    Hegg, R.
    Im, S-A.
    Wright, G. S.
    Henschel, V.
    Molinero, L.
    Chui, S. Y.
    Funke, R.
    Husain, A.
    Winer, E. P.
    Loi, S.
    Emens, L. A.
    ANNALS OF ONCOLOGY, 2018, 29 : 707 - 708
  • [26] IMpassion031: A phase III study comparing neoadjuvant atezolizumab (atezo) vs placebo in combination with anthracycline/nab- paclitaxel (nab-pac)-based chemotherapy in early triple-negative breast cancer (eTNBC)
    Mittendorf, E. A.
    Barrios, C. H.
    Harbeck, N.
    Jung, K. H.
    Miles, D.
    Saji, S.
    Zhang, H.
    Duc, A-N.
    Rafii, S.
    Lai, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] Cost-effectiveness of combined atezolizumab/nab-paclitaxel for advanced triple-negative breast cancer.
    Salans, Mia A.
    Cherry, Daniel R.
    Yip, Anthony T.
    Courtney, Patrick T.
    Kumar, Abhishek
    Murphy, James Don
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
    Wang, Hanwen
    Ma, Huilin
    Sove, Richard J.
    Emens, Leisha A.
    Popel, Aleksander S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
  • [29] IN SILICO VIRTUAL CLINICAL TRIALS OF ATEZOLIZUMAB AND NAB-PACLITAXEL IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER.
    Wang, H.
    Ma, H.
    Sove, R.
    Emens, L.
    Popel, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S23 - S23
  • [30] IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
    Emens, L. A.
    Adams, S.
    Barrios, C. H.
    Dieras, V. C.
    Iwata, H.
    Loi, S.
    Rugo, H. S.
    Schneeweiss, A.
    Winer, E. P.
    Patel, S.
    Henschel, V.
    Swat, A.
    Kaul, M.
    Molinero, L.
    Chui, S. Y.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1148 - S1148
12345